A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease
- PMID: 27482815
- PMCID: PMC4958308
- DOI: 10.1242/dmm.024588
A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease
Abstract
Glucocerebrosidase is a lysosomal hydrolase involved in the breakdown of glucosylceramide. Gaucher disease, a recessive lysosomal storage disorder, is caused by mutations in the gene GBA1 Dysfunctional glucocerebrosidase leads to accumulation of glucosylceramide and glycosylsphingosine in various cell types and organs. Mutations in GBA1 are also a common genetic risk factor for Parkinson disease and related synucleinopathies. In recent years, research on the pathophysiology of Gaucher disease, the molecular link between Gaucher and Parkinson disease, and novel therapeutics, have accelerated the need for relevant cell models with GBA1 mutations. Although induced pluripotent stem cells, primary rodent neurons, and transfected neuroblastoma cell lines have been used to study the effect of glucocerebrosidase deficiency on neuronal function, these models have limitations because of challenges in culturing and propagating the cells, low yield, and the introduction of exogenous mutant GBA1 To address some of these difficulties, we established a high yield, easy-to-culture mouse neuronal cell model with nearly complete glucocerebrosidase deficiency representative of Gaucher disease. We successfully immortalized cortical neurons from embryonic null allele gba(-/-) mice and the control littermate (gba(+/+)) by infecting differentiated primary cortical neurons in culture with an EF1α-SV40T lentivirus. Immortalized gba(-/-) neurons lack glucocerebrosidase protein and enzyme activity, and exhibit a dramatic increase in glucosylceramide and glucosylsphingosine accumulation, enlarged lysosomes, and an impaired ATP-dependent calcium-influx response; these phenotypical characteristics were absent in gba(+/+) neurons. This null allele gba(-/-) mouse neuronal model provides a much-needed tool to study the pathophysiology of Gaucher disease and to evaluate new therapies.
Keywords: Gaucher disease; Glucocerebrosidase; Glucosylceramide; Glucosylsphingosine; Neuron.
© 2016. Published by The Company of Biologists Ltd.
Conflict of interest statement
The authors declare no competing or financial interests.
Figures
Similar articles
-
A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.J Neurosci. 2016 Jul 13;36(28):7441-52. doi: 10.1523/JNEUROSCI.0636-16.2016. J Neurosci. 2016. PMID: 27413154 Free PMC article.
-
Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.J Clin Invest. 2002 May;109(9):1215-21. doi: 10.1172/JCI14530. J Clin Invest. 2002. PMID: 11994410 Free PMC article.
-
Validation of anti-glucocerebrosidase antibodies for western blot analysis on protein lysates of murine and human cells.Biochem J. 2019 Jan 25;476(2):261-274. doi: 10.1042/BCJ20180708. Biochem J. 2019. PMID: 30578288
-
Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.J Neurochem. 2016 Oct;139 Suppl 1:198-215. doi: 10.1111/jnc.13517. Epub 2016 Feb 10. J Neurochem. 2016. PMID: 26860955 Review.
-
Glucocerebrosidase and its relevance to Parkinson disease.Mol Neurodegener. 2019 Aug 29;14(1):36. doi: 10.1186/s13024-019-0336-2. Mol Neurodegener. 2019. PMID: 31464647 Free PMC article. Review.
Cited by
-
What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson's Disease?Int J Mol Sci. 2024 Jan 29;25(3):1641. doi: 10.3390/ijms25031641. Int J Mol Sci. 2024. PMID: 38338925 Free PMC article. Review.
-
Live cell in situ lysosomal GCase activity correlates to alpha-synuclein levels in human differentiated neurons with LRRK2 and GBA1 mutations.Front Cell Neurosci. 2023 Oct 16;17:1229213. doi: 10.3389/fncel.2023.1229213. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37908374 Free PMC article.
-
iPSC-derived neural precursor cells engineering GBA1 recovers acid β-glucosidase deficiency and diminishes α-synuclein and neuropathology.Mol Ther Methods Clin Dev. 2023 Mar 15;29:185-201. doi: 10.1016/j.omtm.2023.03.007. eCollection 2023 Jun 8. Mol Ther Methods Clin Dev. 2023. PMID: 37063480 Free PMC article.
-
Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct.Nat Commun. 2023 Apr 12;14(1):2057. doi: 10.1038/s41467-023-37632-4. Nat Commun. 2023. PMID: 37045813 Free PMC article.
-
PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases.Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2210442120. doi: 10.1073/pnas.2210442120. Epub 2022 Dec 27. Proc Natl Acad Sci U S A. 2023. PMID: 36574647 Free PMC article.
References
-
- Beutler E. and Grabowski G. A. (2001). Gaucher disease. In The Metabolic & Molecular Bases of Inherited Disease (ed. Scriver C. B. A., Beaudet A. L., Sly W. S. and Valle D.), pp. 3635-3668. New York: McGraw-Hill.
-
- Chiasserini D., Paciotti S., Eusebi P., Persichetti E., Tasegian A., Kurzawa-Akanbi M., Chinnery P. F., Morris C. M., Calabresi P., Parnetti L. et al. (2015). Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies. Mol. Neurodegener. 10, 15 10.1186/s13024-015-0010-2 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
